PSA Nadir After RT+ADT for Prostate Cancer Predicts Outcomes
New findings could have a role in conducting clinical trials of novel systemic therapies.
New findings could have a role in conducting clinical trials of novel systemic therapies.
The increasing number of indications for second-generation antiandrogens may result in a large group of men at risk for toxic effects, according to investigators.
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
Investigators report results from the phase 3 randomized EMBARK trial.
Cardiovascular disease is a leading cause of noncancer death in men with prostate cancer.
PSA response is an important early indicator of progression-free survival in mHSPC.
In a study of oligometastatic castration-sensitive prostate cancer, metastasis-directed therapy (MDT) with concurrent ADT vs MDT alone was significantly associated with a greater 5-year rate of freedom from biochemical progression.
Investigators observed no significant difference in development of castration-resistant prostate cancer and overall mortality.